Trial Profile
An Observational Study Design to Detect if Co-stimulatory Markers and Vitamin D Status in Anti-PD-1 Treated Advanced Melanoma Patients Can Predict Treatment Outcome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- 16 Feb 2022 Status changed from recruiting to completed.
- 27 Jan 2020 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2020.
- 27 Jun 2017 New trial record